# A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

> **NCT03833206** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **BioLite, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** PDC-1421 Capsule

## Key facts

- **NCT ID:** NCT03833206
- **Lead sponsor:** BioLite, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-15
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833206, "A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03833206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*